Cohen-Jonathan E - Search Results

1

The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras.

Cohen-Jonathan E, Evans SM, Koch CJ, Muschel RJ, McKenna WG, Wu J, Bernhard EJ. Cohen-Jonathan E, et al. Cancer Res. 2001 Mar 1;61(5):2289-93. Cancer Res. 2001. PMID: 11280800

2

Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS.

Cohen-Jonathan E, Muschel RJ, Gillies McKenna W, Evans SM, Cerniglia G, Mick R, Kusewitt D, Sebti SM, Hamilton AD, Oliff A, Kohl N, Gibbs JB, Bernhard EJ. Cohen-Jonathan E, et al. Radiat Res. 2000 Aug;154(2):125-32. doi: 10.1667/0033-7587(2000)154[0125:fiptae]2.0.co;2. Radiat Res. 2000. PMID: 10931682

3

Farnesyltransferase inhibitor effects on prostate tumor micro-environment and radiation survival.

Shi Y, Wu J, Mick R, Cerniglia GJ, Cohen-Jonathan E, Rhim JS, Koch CJ, Bernhard EJ. Shi Y, et al. Prostate. 2005 Jan 1;62(1):69-82. doi: 10.1002/pros.20122. Prostate. 2005. PMID: 15389805

4

The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft.

Delmas C, End D, Rochaix P, Favre G, Toulas C, Cohen-Jonathan E. Delmas C, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):6062-8. Clin Cancer Res. 2003. PMID: 14676133

5

The farnesyltransferase inhibitor FTI-277 suppresses the 24-kDa FGF2-induced radioresistance in HeLa cells expressing wild-type RAS.

Cohen-Jonathan E, Toulas C, Ader I, Monteil S, Allal C, Bonnet J, Hamilton AD, Sebti SM, Daly-Schveitzer N, Favre G. Cohen-Jonathan E, et al. Radiat Res. 1999 Oct;152(4):404-11. Radiat Res. 1999. PMID: 10477917

6

Farnesyltransferase inhibitor, R115777, reverses the resistance of human glioma cell lines to ionizing radiation.

Delmas C, Heliez C, Cohen-Jonathan E, End D, Bonnet J, Favre G, Toulas C. Delmas C, et al. Int J Cancer. 2002 Jul 1;100(1):43-8. doi: 10.1002/ijc.10439. Int J Cancer. 2002. PMID: 12115585

7

Radioresistance induced by the high molecular forms of the basic fibroblast growth factor is associated with an increased G2 delay and a hyperphosphorylation of p34CDC2 in HeLa cells.

Cohen-Jonathan E, Toulas C, Monteil S, Couderc B, Maret A, Bard JJ, Prats H, Daly-Schveitzer N, Favre G. Cohen-Jonathan E, et al. Cancer Res. 1997 Apr 1;57(7):1364-70. Cancer Res. 1997. PMID: 9102225

8

RhoB controls the 24 kDa FGF-2-induced radioresistance in HeLa cells by preventing post-mitotic cell death.

Ader I, Toulas C, Dalenc F, Delmas C, Bonnet J, Cohen-Jonathan E, Favre G. Ader I, et al. Oncogene. 2002 Sep 5;21(39):5998-6006. doi: 10.1038/sj.onc.1205746. Oncogene. 2002. PMID: 12203112

9

Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial.

Bachaud JM, Cohen-Jonathan E, Alzieu C, David JM, Serrano E, Daly-Schveitzer N. Bachaud JM, et al. Int J Radiat Oncol Biol Phys. 1996 Dec 1;36(5):999-1004. doi: 10.1016/s0360-3016(96)00430-0. Int J Radiat Oncol Biol Phys. 1996. PMID: 8985019 Clinical Trial.

10

Increased expression of a COOH-truncated nucleophosmin resulting from alternative splicing is associated with cellular resistance to ionizing radiation in HeLa cells.

Dalenc F, Drouet J, Ader I, Delmas C, Rochaix P, Favre G, Cohen-Jonathan E, Toulas C. Dalenc F, et al. Int J Cancer. 2002 Aug 20;100(6):662-8. doi: 10.1002/ijc.10558. Int J Cancer. 2002. PMID: 12209603

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters